×

MorphoSys to Present Data on Proprietary Programs at American Society of Clinical Oncology Annual Meeting

MARTINSRIED / MUNICH, Germany, May 13, 2015 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced the publication of three MorphoSys abstracts which were submitted to the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting to take place from May 29 to June 2 in Chicago, Illinois. The abstracts include pre-clinical and first clinical data on the Company's proprietary drug candidate MOR202 from a Phase 1/2a study in patients with multiple myeloma and updated clinical data for the MOR208 program.

"We are delighted to publish a substantial package of clinical and preclinical data at the preeminent conference on clinical oncology. The data set provides additional insight into the progress of our lead cancer compounds MOR208 and MOR202," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "For MOR202, we are in particular looking forward to presenting not only safety data but also first efficacy data from the Phase 1/2a study in multiple myeloma."

List of abstracts:

Abstract #8574

A phase 1/2a study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).

The poster presentation will include the in the abstract described safety results and additional first efficacy results. The poster presentation will take place on Sunday, May 31, 8:00 AM - 11:30 AM CDT, as part of the Lymphoma and Plasma Cell Disorders track.

Abstract #8588

Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.

The poster presentation will take place on Sunday, May 31, 8:00 AM - 11:30 AM CDT, as part of the Lymphoma and Plasma Cell Disorders track.

Abstract #8500

Phase 2a study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

The oral presentation will take place Monday, Jun 1, 9:45 AM - 9:57 AM CDT, as part of the Lymphoma and Plasma Cell Disorders track.

Additionally, MorphoSys's partners will present data for several HuCAL antibodies, which are currently in clinical development:

Abstract #3004

A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL.

Abstract #590

Phase 1 study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).

Abstract #7508

Final results of phase 1b of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

The full abstracts can be accessed online athttp://abstracts.asco.org/.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Manager Corporate Communications & IR

Jessica Rush
Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Media Release http://hugin.info/130295/R/1921618/688764.pdf

HUG#1921618

Source:MorphoSys AG